Bluepharma invests €30M in industrial unit for oncology drugs

2023-03-20

The investment totals €30million ($32million) which has provided the plant in Portugal, one of Europe’s largest for the production of medicnes, with these specifications.

The new unit in Eiras, Coimbra, has created 100 mostly highly-qualified jobs.

This production unit materializes the ONConcept project, which brought Bluepharma together in a partnership with two German companies in the pharmaceutical area - Helm and Welding.

Bluepharma says the new unit represents an important role to Europe's reindustrialization strategy, while being an important contribution to the sustainability of the health systems and accessibility of life-changing medicines to oncology patients.

The company operates as a CDMO and offers an integrated approach from development to commercial manufacturing. With Helm and Welding, the collaboration will use its scientific and regulatory knowledge, growing the active pharmaceutical ingredients (API) network offering its own intellectual property service, strengthening the individual market knowledge and a strong highly potent products portfolio of those made in Europe.

The ONConcept project has built a basket of more than 20 products providing a stream of new opportunities to its partners, with some molecules open to off-patient competition now while others will have dates for later in the decade.

The company saus that in the coming years, the strategic alliance wants to become known as a reputable European supplier of highly potent drugs with the capabilities needed to develop, register, and supply complex products, ensuring competitiveness across the product lifecycle.

googletag.cmd.push(function () {

googletag.display('text-ad1');

});

The launch ceremony was attended by a number of national and international dignitaries including the Portuguese Minister of Economy and Sea, António Costa Silva, the President of Medicines for Europe, Elisabeth Stampa, and the President of Bluepharma, Paulo Barradas Rebelo.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构